Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.78 |
| ▸ | MAOB | P27338 | 6/20 | 0.78 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.78 |
| ▸ | SDHA | P31040 | 2/20 | 0.78 |
| ▸ | LMNA | P02545 | 1/20 | 0.78 |
| ▸ | CALML3 | P27482 | 1/20 | 0.78 |
| ▸ | F10 | P00742 | 7/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6058550 | 1.00 | MAOA (0.78) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL27596950 | 0.94 | MAOA (0.72) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL18408751 | 0.94 | MAOA (0.75) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL7103707 | 0.94 | MAOA (0.72) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL7103704 | 0.94 | MAOA (0.72) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL4165575 | 0.93 | MAOA (0.68) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL4165577 | 0.93 | MAOA (0.68) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL5220160 | 0.91 | MAOB (0.65) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL24169975 | 0.91 | MAOB (0.64) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL18410474 | 0.91 | MAOB (0.64) | MAOAMAOBPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1057087-C | Substituted oxazine and thiazine oxazolidinone antimicrobials | UPJOHN CO (US) | 2000-10-04 | — | — | CN | claimed |
| EP-0717738-B1 | SUBSTITUTED OXAZINE AND THIAZINE OXAZOLIDINONE ANTIMICROBIALS | UPJOHN CO (US) | 1999-10-20 | — | — | EP | claimed |
| CN-1130379-A | Substituted oxazine and thiazine oxazolidinone antimicrobials | UPJOHN CO (US) | 1996-09-04 | — | — | CN | claimed |
| EP-3932917-A2 | SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY | The Global Alliance for TB Drug Development, Inc. (US) | 2022-01-05 | — | — | EP | disclosed |
| US-20200148651-A1 | SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) | 2020-05-14 | — | — | US | disclosed |
| US-10550092-B2 | Substituted phenyloxazolidinones for antimicrobial therapy | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20180179168-A1 | SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. | 2018-06-28 | — | — | US | disclosed |
| WO-2017015106-A1 | SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2017-01-26 | — | — | WO | disclosed |
| EP-1467992-B1 | ANTIMICROBIAL DIHYDROTHIAZINE AND DIHYDROTHIOPYRAN OXAZOLIDINONES | PHARMACIA & UPJOHN CO LLC (US) | 2007-08-08 | — | — | EP | disclosed |
| US-7101874-B2 | Antimicrobial dihydrothiazine and dihydrothiopyran oxazolidinones | PHARMACIA AND UPJOHN COMPANY (US) | 2006-09-05 | — | — | US | disclosed |
| CN-1221548-C | Oxazolidinones having sulfoximine functionality and their use as antimicrobial agents | UPJOHN CO (US) | 2005-10-05 | — | — | CN | disclosed |
| EP-1467992-A1 | ANTIMICROBIAL DIHYDROTHIAZINE AND DIHYDROTHIOPYRAN OXAZOLIDINONES | PHARMACIA & UPJOHN COMPANY (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20030232812-A1 | Antimicrobial dihydrothiazine and dihydrothiopyran oxazolidinones | PHARMACIA & UPJOHN COMPANY | 2003-12-18 | — | — | US | disclosed |
| US-20030171331-A1 | The present invention describes a novel cotherapy of oxazolidinones and at least one vitamin selected from vitamin B2, vitamin B6, vitamin B12 and folic acid. | PHARMACIA & UPJOHN COMPANY | 2003-09-11 | — | — | US | disclosed |
| WO-2003062231-A1 | ANTIMICROBIAL DIHYDROTHIAZINE AND DIHYDROTHIOPYRAN OXAZOLIDINONES | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-31 | — | — | WO | disclosed |
| CN-1391572-A | Oxazolidinones having sulfoximine functionality and their use as antimicrobial agents | UPJOHN CO (US) | 2003-01-15 | — | — | CN | disclosed |
| US-20010046987-A1 | Oxazolidinones having a sulfoximine functionality | PHARMACIA & UPJOHN COMPANY | 2001-11-29 | — | — | US | disclosed |
| CN-1057087-C | Substituted oxazine and thiazine oxazolidinone antimicrobials | UPJOHN CO (US) | 2000-10-04 | — | — | CN | disclosed |
| EP-0717738-B1 | SUBSTITUTED OXAZINE AND THIAZINE OXAZOLIDINONE ANTIMICROBIALS | UPJOHN CO (US) | 1999-10-20 | — | — | EP | disclosed |
| CN-1130379-A | Substituted oxazine and thiazine oxazolidinone antimicrobials | UPJOHN CO (US) | 1996-09-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179168-A1 | SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY | THPO, TBCD, OXA1L | MAOA 2234/4885MAOB 1541/4885PTGS1 1413/4885 |
| US-20030232812-A1 | Antimicrobial dihydrothiazine and dihydrothiopyran oxazolidinones | DHX35, ZYX, DHX15 | MAOA 3803/4885MAOB 3725/4885PTGS1 2634/4885 |
| US-20010046987-A1 | Oxazolidinones having a sulfoximine functionality | OXA1L, SULT1A1, SULT1E1 | MAOA 923/4885MAOB 726/4885PTGS1 311/4885 |
| US-20200148651-A1 | SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY | THPO, TBCD, OXA1L | MAOA 2234/4885MAOB 1541/4885PTGS1 1413/4885 |
| US-10550092-B2 | Substituted phenyloxazolidinones for antimicrobial therapy | THPO, TBCD, OXA1L | MAOA 2234/4885MAOB 1541/4885PTGS1 1413/4885 |
| US-20030171331-A1 | The present invention describes a novel cotherapy of oxazolidinones and at least one vitamin selected from vitamin B2, vitamin B6, vitamin B12 and folic acid. | DHFR, MMAB, FOLR2 | MAOA 252/4885MAOB 13/4885PTGS1 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.